Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:1069-1070 (26 May), doi:10.1136/bmj.39216.583333.80
Inadequacies in care should not be masked by the indiscriminate use of symptom controlling drugs
| The first 150 words of the full text of this article appear below. |
The core problems of autismthose involving social interaction, communication, and restricted and repetitive activitiescan be compounded by behavioural problems, including severe tempers, aggression, and irritability.1 Severe aggression places a special burden on carers; it is more common in people with marked intellectual retardation and is related to poor daily living skills and impaired communication. Currently, no drugs are available to treat the underlying autistic condition. Specialised educational programmes, behaviour therapy, and environmental changes can improve aggressive behaviour,1 but if they fail drug treatments should be considered.2 Behavioural problems related to depression or attention deficit can be addressed by relevant therapy; but if the problem of aggression is unresponsive to these manoeuvres the need for symptom control arises. Major tranquillisers in particular have been used off-label, but their place has been uncertain because of doubts about safety and (until recently) efficacy.
Two well conducted double blind placebo controlled studies have compared
Susan Morgan, medical assessor1, Eric Taylor, professor of child and adolescent psychiatry2
1 Medicines and Healthcare Products Regulatory Agency, London SW8 5NQ, 2 Institute of Psychiatry, King's College, London SE5 8AF
susan.morgan@mhra.gsi.gov.uk
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+